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Abstract
Background: Standard therapy for metastatic non small cell lung cancer (NSCLC) includes palliative systemic
chemotherapy and/or radiotherapy. Recent studies of patients with limited metastases treated with curative-intent
stereotactic body radiation therapy (SBRT) have shown encouraging survival. We hypothesized that patients treated
with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for
Stage III NSCLC.
Methods: We retrospectively reviewed the records of NSCLC patients treated with curative-intent radiotherapy at
the University of Rochester from 2000-2008. We identified 3 groups of patients with NSCLC: stage III, stage IV, and
recurrent stage IV (initial stage I-II). All stage IV NSCLC patients treated with SBRT had ≤ 8 lesions.
Results: Of 146 patients, 88% had KPS ≥ 80%, 30% had > 5% weight loss, and 95% were smokers. The 5-year OS
from date of NSCLC diagnosis for stage III, initial stage IV and recurrent stage IV was 7%, 14%, and 27%
respectively. The 5-year OS from date of metastatic diagnosis was significantly (p < 0.00001) superior among those
with limited metastases (≤ 8 lesions) versus stage III patients who developed extensive metastases not amenable
to SBRT (14% vs. 0%).
Conclusion: Stage IV NSCLC is a heterogeneous patient population, with a selected cohort apparently faring better
than Stage III patients. Though patients with limited metastases are favorably selected by virtue of more indolent
disease and/or less bulky disease burden, perhaps staging these patients differently is appropriate for prognostic
and treatment characterization. Aggressive local therapy may be indicated in these patients, though prospective
clinical studies are needed.
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Background
Non-small cell lung cancer (NSCLC) is the leading
cause of cancer mortality in the United States [1].
Patients with stage IV NSCLC typically have a poor
prognosis, with a median survival of 8 months [2]. Pal-
liative systemic therapy improves survival and disease
control, though careful selection of patients suitable for
systemic therapy is critical. Radiation treatment for
symptomatic relief is a common approach utilized by
many clinicians.
Stage IV NSCLC represents a heterogeneous stage
grouping, with regard to the extent of disease spread,
cancer burden (i.e. bulk), performance status, and other
prognostic factors. As previously postulated by Drs.
Hellman and Weichselbaum, the metastatic disease state
lies on a spectrum rather than occupying a finite point
[3]. Thus, the definition of metastatic disease could be
refined in terms of limited versus extensive disease
extent and/or disease bulk Patients with limited meta-
static disease and good performance have been shown
to have better outcomes following aggressive local treat-
ments, i.e. resection, stereotactic body radiotherapy
(SBRT), radiofrequency ablation [4].
In previous studies from the University of Rochester,
we defined oligometastases as the presence of 5 or fewer
clinically apparent metastases [5,6]. Recent studies,
including our own, suggest that patients with limited
metastases who receive curative-intent SBRT to
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involvement, have encouraging survival [7,8]. SBRT
implies the use of hypofractionated, highly conformal
external beam radiotherapy, utilizing technology to
improve targeting accuracy, such as external or internal
stereotactic fiducial markers and/or image guidance.
Although data on SBRT treatment for limited metas-
tases from breast cancer and colon cancer have been
encouraging, there is limited outcome data following
SBRT for metastatic NSCLC. We hypothesized that
curative-intent SBRT for limited metastatic (i.e., select
stage IV) NSCLC results in comparable outcomes rela-
tive to stage III NSCLC treated with aggressive curative
intent treatment.
Methods
We retrospectively reviewed the records of patients with
NSCLC who were treated at the University of Rochester
from 2000-2008 with curative-intent radiotherapy (with
or without chemotherapy) for stage III NSCLC or SBRT
for limited stage IV NSCLC, defined as metastatic dis-
ease treated with curative-intent. The study was
approved by the University of Rochester Research Sub-
jects Review Board.
Those patients with metastases limited in number
and extent, clinically determined to be amenable to
SBRT, were defined as having limited metastases.
While previous prospective studies from our group
[5,6] defined limited metastases/oligometastases as 5 or
fewer lesions, in this study, six NSCLC patients with
6-8 metastatic lesions were considered to have limited
metastatic NSCLC, as all radiographically apparent
lesions were amenable to SBRT as defined by our pre-
viously published normal tissue tolerances for SBRT
[9]. Several patients underwent repeat courses of SBRT
for either additional lesions or for lesions that recurred
after SBRT.
Patients with metastases from NSCLC to any organ(s),
including brain, bone, liver,o rl u n gw e r ei n c l u d e di n
this study. Only patients with biopsy-proven NSCLC
were included. Those with prior curative-intent treat-
ment of metastatic tumors (i.e. surgery) were not
excluded. Patients with new solitary lung lesions, ques-
tionable for metachronous stage I NSCLC versus solitary
metastases were excluded.
The 7th AJCC Staging system was used to categorize
patients into 3 groups: those who were stage III at
initial diagnosis, those who presented with stage IV
NSCLC, and those with stage I/II NSCLC who later
developed recurrent stage IV disease. Among patients
with Stage III NSCLC, metastatic recurrence was char-
acterized as limited metastatic (defined above) or
extensive metastatic (not amenable to curative-intent
SBRT) disease.
All patients were assessed with diagnostic CT or PET/
CT imaging to identify metastatic lesions. Brain metas-
tases were assessed with MRI. In some patients bone
metastases were identified with bone scan and/or MRI.
Patients who had brain metastases were treated cura-
tively with surgery and/or stereotactic radiosurgery.
Those that received surgery for brain metastases had
SBRT to other sites of metastatic disease. A variety of
chemotherapeutic or radio-sensitizing agents were
utilized.
The net gross tumor volume (GTV) was documented
as the sum of GTVs of the primary and/or metastatic
sites. The GTVs were based on the contoured volumes
on the planning CT scan(s). Previously resected metas-
tases were not included in the net tumor volume.
T h i ss t u d yw a sa p p r o v e db yt h eU n i v e r s i t yo fR o c h e -
ster Research Subjects Review Board.
Conventional Radiotherapy
Stage III patients underwent a CT simulation for treat-
ment planning purposes. Definitive radiotherapy was
given concurrently with chemotherapy or as adjuvant
treatment following surgery. A 3D conformal technique
was utilized to shape the dose around the tumor volume
with an appropriate volumetric expansion. The average
dose prescribed was 60 Gy but ranged from 45 to 66
Gy.
SBRT Technique
SBRT was delivered through the Novalis Exac Trac
®
System. All patients were immobilized during simulation
and treatment using a vacuum cushion device. An end-
expiratory or shallow breath-hold technique was used in
conjunction with the ExacTrac
® patient positioning plat-
form (BrainLAB
®, AG, Heimstetten, Germany) to accu-
rately reproduce patient set-up during treatments. The
ExacTrac
® system consists of external body fiducial
markers monitored in real time by two ceiling mounted
infrared cameras. Treatment planning was performed
with BrainLAB planning software. SBRT was delivered
using conformal arcs, and the dose was prescribed to
the isocenter with the 80% isodose line covering the
planning target volume (PTV). The treatment volume
included a 7-10 mm volumetric expansion of the GTV.
Typically, the dose schedule was 50-60 Gy in 5-10 frac-
tions. Depending on the location of the lesion and the
dose volume histogram of the organs at risk, a more
hypofractionated schedule was utilized in 5 fractions.
Our institution has adapted a 10 fraction scheme of
treating patients with SBRT to reduce potential toxicity
while preserving control. Typically peripheral lung
lesions were treated with 5 fractions to 50 Gy, while
more central lung lesions, adrenal, liver, abdominal/pel-
vic lymph node metastases were treated with 10 frac-
tions to 50 Gy.
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The primary endpoint was overall survival (OS). OS was
calculated in two manners: from the date of initial
N S C L Cd i a g n o s i s ,a sw e l la sf r o mt h ed a t eo ff i r s t
metastases, to date of last follow-up or death, using
Kaplan-Meier actuarial survival analyses. OS was mea-
sured from date of initial diagnosis to compare out-
comes of limited stage IV and Stage III NSCLC patients.
As an alternate measure of OS, the date of first metas-
tases was used as a reference point to compare the out-
comes of recurrent metastatic patients versus those who
presented with initial limited metastatic disease. Univari-
ate analyses (UVA) were performed with log-rank tests
(for discrete variables) or Cox regression analyses (for
continuous variables). Significant (p ≤ 0.05) variables on
UVA were tested with multivariate analyses (MVA),
using a Cox proportional hazards regression model. Chi
square tests and ANOVA tests were used to compare
patient and tumor characteristics between the sub-
groups. Stata version 9.2 was used for all data analyses.
The retrospective nature of this study did not allow for
detailed assessment of treatment toxicity; previous
reports from our group have suggested minimal adverse
effects after SBRT [10,11].
Results
Patient and disease characteristics
Patient and disease characteristics are summarized in
Additional file 1. From 2000- 2008, 146 patients were
eligible for analysis. Patient age ranged from 35 - 85
years (median 65 years). Eighty-eight percent had Kar-
nofsky performance status (KPS) ≥ 80%, and 30% had >
5% weight loss at time of diagnosis. The majority of
patients (95%) had a prior smoking history. One-hun-
dred patients received chemotherapy during the course
of their cancer treatment, and 22 patients underwent
prior resection of their primary lung mass. Thirteen
patients had curative resection of a metastatic lesion
prior to their course of SBRT. Metastatic sites apparent
at the time of SBRT for limited metastases included
lung or thoracic lymph nodes (n = 22), liver (n = 13),
adrenal glands (n = 16), bone (n = 7), retroperitoneal
l y m p hn o d e( n=2 ) ,a n dC N S( n=1 0 ) .T h i r t e e n
patients developed brain metastases at the time of
extensive metastatic progression (n = 13). The net GTV
ranged from 0.9 - 877.1 ml (median 85.7 ml). Compared
to stage III patients, those with initial limited Stage IV
disease had less bulkier disease (median 93.9 ml vs. 76.5
ml respectively), though not significant (p = 0.27; Addi-
tional File 1).
There were a total of 94 patients (64.3%) categorized
as stage III NSCLC, 38 patients (26.0%) with initial lim-
ited stage IV NSCLC and 14 patients (9.6%) with stage
I/II NSCLC who progressed to limited metastatic stage
IV. Fifty-five of the 94 patients with initial stage III
NSCLC (74%) developed radiographically apparent
metastases, of whom 44 developed limited metastatic
stage IV disease (all with ≤5 lesions), treated with SBRT.
The average time to recurrence for these Stage III
patients was 14.2 months (range 3.2-45.2 months).
Among those with Stage III and Stage IV disease all had
a staging CT or MRI of head. All 38 patients with stage
I VN S C L Ch a dP E T / C Tw h i l e9 0o f9 3p a t i e n t sw i t h
stage III NSCLC had PET/CT.
Outcomes
The OS calculated from time of initial NSCLC diagnosis
is presented in Additional file 2 and Figure 1. The 2-
year and 5-year OS for all patients with stage III
NSCLC was 43% and 7% respectively versus 43% and
14% for initial limited stage IV (p = 0.30).
The OS calculated from the date of diagnosis of meta-
static disease is presented in Additional file 3 and Figure
2. Worse survival was observed in patients with initial
stage I/II or Stage III NSCLC who developed metastases
(5-year OS 0%, with no survivors beyond 4.1 years) ver-
sus those who initially presented with limited metastatic
disease (5-year OS 14%, p = 0.003).
Among those with recurrent stage IV NSCLC (stage I/II,
or III who progressed to stage IV) the patients who
developed limited metastases had a 2-year and 5-year
OS from date of metastatic progression of 25% and 0%
respectively. In contrast, there were no survivors beyond
11.0 months among the 14 patients with stage I/II or III
NSCLC who developed extensive metastatic disease (p <
0.00001). For patients with initial diagnosis of limited
stage IV NSCLC, there was no significant difference
among patients with ≤ 5 metastases versus 6-8 (p =
0.94).
Age, KPS, weight loss, smoking history, stage and net
GTV were assessed for affect on OS from date of initial
NSCLC diagnosis as shown in Additional file 4. On uni-
v a r i a t ea n a l y s i so fO Sf r o md a t eo fi n i t i a lN S C L Cd i a g -
nosis, GTV at time of radiation for initial stage III or IV
NSCLC (p < 0.002) was the only variable which was sta-
tistically. Stage III versus limited metastatic Stage IV
trended (p = 0.078) towards worse OS. MVA models for
OS were also assessed with the same variables; net GTV
remained a statistically significant (p = 0.001) factor for
predicting OS. MVA using only stage and GTV did not
change the results. MVA models for OS from date of
metastases treated with SBRT were assessed, with the
same variables. Net GTV of metastases treated with
SBRT was not statistically significant (p = 0.39).
Discussion
The standard treatment for metastatic NSCLC is
systemic therapy. However, in those patients with
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Page 3 of 7Figure 2 represents the overall survival from date of failure. The blue line represents Stage III which progressed to Stage IV, green line
represents the Stage I/II patients that progressed to Stage IV, and lastly the maroon line represents initial stage IV patients.
Figure 1 represents the overall survival from date of diagnosis for the various stage groupings. The blue line represents Stage III (whom
did not progress to Stage IV, maroon line represents Stage III which progressed to Stage IV, green line represents the initial stage IV patients
and lastly the gold line represents the Stage I/II patients that progressed to Stage IV.
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or ablative treatments have shown to be beneficial. Ser-
ies describing surgical metastectomy have the largest
patient numbers and longest follow up [12-14]. Surgical
metastatectomy is proposed to be a curative therapy,
resulting in prolonged disease-free survival [15].
Recently, there is an expanding experience with stereo-
tactic radiotherapy as effective local therapy for meta-
static lesions from any primary cancer. Local control
rates of 60-90% have been reported for metastatic
tumors involving spine, lung, and liver [16-20].
In this study, patients with initial stage IV NSCLC
treated with aggressive local therapy had a higher 5-year
OS when compared to stage III NSCLC patients treated
with curative intent (14% and 7%, respectively).
Although our 5-year survival rate of 7% for Stage III
NSCLC patients is lower than what is reported in Phase
II-III studies of definitive radiation, our Stage III
patients represent an unselected cohort of all patients
seen in our clinic, many of whom had adverse prognos-
tic factors such as poor performance status and/or sig-
nificant weights loss, unlike most patients receiving
chemoradiation/radiation on prospective studies [21,22].
Most of our patients with Stage III NSCLC had bulky
disease, and many would not qualify for prospective stu-
dies because of poor performance status and/or > 5%
weight loss (Additional file 1). The 5-year OS rate of
patients presenting with limited stage IV NSCLC, which
is a selected cohort of patients with disease amenable to
SBRT, was similar to those with stage III NSCLC that
did not metastasize, suggesting that a number of
patients in AJCC stage IV group would be more appro-
priately classified as stage III NSCLC in future AJCC
s t a g i n g .T h e s ed a t as u p p o r tt h eh y p o t h e s i st h a ts e l e c t
patients with stage IV NSCLC have excellent outcomes
comparable to unselected patients with stage III disease
when treated aggressively with SBRT.
Patients with initial limited stage IV NSCLC fared bet-
ter than those with stage I/II or III NSCLC who later
progressed to stage IV (5-year OS 22% versus 0% from
time of metastatic diagnosis). Perhaps limited metastases
presenting as Stage IV NSCLC is biologically more
responsive to cancer therapy than recurrent disease.
There may be a period during which local therapy
may be most beneficial for patients who initially present
with limited metastatic disease. Studies have shown that
effective chemotherapy can reduce the number and sites
of metastatic tumors at which time, local therapy may
be considered [23-25]. Rusthoven et al reported that
after NSCLC patients receive systemic chemotherapy for
limited metastases, the majority (64%) progressed with
local failure only; the time to progression in these
patients was 3 - 4 months, thereby providing a critical
window during which curative local therapy could be
offered. Researchers from the University of Chicago
analyzed the patterns of recurrence among 38 patients
with stage IIIB and IV NSCLC who were enrolled on a
Phase II trial of oxaliplatin and paclitaxel [24]. Half of
the patients (19/38) had stable disease or progressed in
the original sites only without developing new lesions
after the completion of chemotherapy. Seventeen
patients who had limited disease (≤ 4 metastatic sites) at
initial presentation had a higher propensity to have
stable disease or progress only at the initially involved
sites. These studies demonstrate that there is a point at
which progression of metastatic disease (i.e., develop-
ment of new lesions) may be suppressed by systemic
chemotherapy, allowing for aggressive local treatment to
address residual disease.
The role of combined modality treatment for meta-
static NSCLC patients was investigated by Khan, et al in
a retrospective series of 23 patients with oligometastatic
(1-2 sites) NSCLC disease [25]. These patients received
curative treatment for their primary thoracic disease and
subsequently received local treatment for their meta-
static sites. At 28 months, overall survival was 22% with
median survival of 20 months. In our study, patients
with initial limited metastatic NSCLC treated with
SBRT had a 2-year OS of 48% - this difference could be
attributed to differences in patients or cancer character-
istics or perhaps recent improvements in systemic che-
motherapy and local treatment techniques. With a
combined modality approach, the potential for further
metastatic disease dissemination may be minimized,
thus potentially translating to improved OS.
Among patients with recurrent metastatic NSCLC,
those with limited metastases (2-year survival of 24%)
had superior outcomes compared to those with exten-
sive disease (no survivors beyond 11.0 months). This is
consistent with the hypothesis that a larger tumor bur-
den may predict for increased risk of local failure and
metastatic potential. Among patients with limited
metastases treated with curative intent SBRT, there were
not significant differences in survival between those with
≤ 5 metastases versus 6-8 metastases, and in fact their
survival is equivalent at 47 months. While small patient
numbers limit analyses, this suggests that other variables
such as tumor bulk and/or tumor location are more cri-
tical than number of lesions. Previous studies from our
group of patients who underwent SBRT for limited
metastases (not necessarily from NSCLC) [10,11,26]
have shown net GTV to significantly impact disease
control and survival outcomes.
In patients with non-metastatic NSCLC, numerous
studies suggest that tumor burden correlates with prog-
nosis [27-30]. In a small cohort of 19 patients with stage
I-III NSCLC, Lee et al reported that tumor volume > 25
cc measured on PET CT scan was associated with
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to be a poor prognostic factor in lung cancer. Similarly,
Bradley et al. demonstrated the prognostic value of
GTV determined on planning CT scans to be associated
with OS and local tumor control. This correlation
appears to persist for patients with metastatic NSCLC
[31] as reported by Oh et al and our present observa-
tions in which net GTV predicted for improved OS
(MVA p < 0.0001). However, GTV of metastatic sites
treated with SBRT was not significantly correlated with
OS. The GTV of metastatic sites included patients with
initial Stage III who developed limited metastases.
Weaknesses of our study include the retrospective
nature of the analyses, heterogeneity of patient treat-
ment, including various systemic therapy regimens
(which was not presented), heterogeneity of involved
metastatic sites (which was not analyzed) and, for some
patient subgroups, relatively small patient numbers.
Strengths of our study include an overall relatively large
study population (particularly unselected Stage III
patients and select patients with limited metastases
from NSCLC) allowing for the analysis of several prog-
nostic variables.
Stage IV NSCLC represents a heterogeneous patient
population. Those patients with limited tumor burden
in terms of volume and number of lesions are amenable
to, and may benefit from focal ablative therapy to
known sites of disease. In our study, select patients with
limited stage IV NSCLC treated with curative-intent
SBRT, have similar outcomes compared to those unse-
lected patients with stage III NSCLC. While the benefit
of SBRT (or other ablative therapies) for limited meta-
static NSCLC has not been definitively proven from
controlled randomized studies, even with the possibility
of no benefit from ablative therapies, select patients
with Stage IV NSCLC fare relatively well, and perhaps
warrant unique consideration in future AJCC stage
groupings. It reasonable to postulate that these patients
fare well by virtue of a less indolent disease process in
conjunction with a therapeutic benefit from ablative
therapy. Given the relatively poor prolonged NSCLC
disease control from systemic therapy, it is difficult to
postulate that ablative therapies are not benefiting
patients. Nonetheless, the favorable outcomes reported
here warrant consideration of further investigation of
local treatment for patients with limited tumor burden.
The University of Chicago has launched a randomized
Phase II trial of patients with 1-5 metastases from
NSCLC to assess the survival with the addition of hypo-
fractionated image guided radiotherapy concurrently
with docetaxel and cisplatin. The NCCTG is also rando-
mizing patients with 1-5 metastases from NSCLC, to
undergo or not undergo radiation (with standard fractio-
nation) to metastatic sites.
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